NCT02645149 2026-02-27
Match Mel
Melanoma Institute Australia
Phase 2 Completed
Clinical Trials
5 trialsNCT01176474 2023-07-19
Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT04435964 2023-03-24
G-DEFINER
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Completed
NCT01176461 2023-01-18
Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00101166 2018-02-28
Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed